In vitro transformation of primary human hepatocytes: Epigenetic changes and stemness properties.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 02 04 2019
revised: 19 09 2019
accepted: 21 09 2019
pubmed: 27 9 2019
medline: 17 6 2020
entrez: 27 9 2019
Statut: ppublish

Résumé

Human hepatocarcinogenesis is a complex process with many unresolved issues, including the cell of origin (differentiated and/or progenitor/stem cells) and the initial steps leading to tumor development. With the aim of providing new tools for studying hepatocellular carcinoma initiation and progression, we developed an innovative model based on primary human hepatocytes (PHHs) lentivirus-transduced with SV40

Identifiants

pubmed: 31557464
pii: S0014-4827(19)30510-5
doi: 10.1016/j.yexcr.2019.111643
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111643

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Floriane Pez (F)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.

Patricia Gifu (P)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.

Davide Degli-Esposti (D)

Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France.

Nadim Fares (N)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.

Anaïs Lopez (A)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.

Lydie Lefrançois (L)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.

Maud Michelet (M)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.

Michel Rivoire (M)

Département de Chirurgie et Institut de Chirurgie Expérimentale, Centre Léon Bérard, Lyon, France.

Brigitte Bancel (B)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France; Hospices Civils de Lyon, Service d'Anatomopathologie, Groupement Hospitalier Lyon Nord, France.

Bakary S Sylla (BS)

Infections and Cancer Biology Group, International Agency for Research on Cancer (IARC), Lyon, France.

Zdenko Herceg (Z)

Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France.

Philippe Merle (P)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France; Hospices Civils de Lyon, Service d'Hépatologie et Gastroentérologie, Groupement Hospitalier Lyon Nord, France.

Claude Caron de Fromentel (C)

INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France. Electronic address: claude.de-fromentel@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH